4D Molecular Therapeutics announced it will present two-year follow-up data from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD), at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in July 2026. The therapy aims to provide multi-year sustained delivery of anti-VEGF biologics with a single injection, potentially reducing treatment burden for patients. The presentation will be given by Dr. Carl Awh and is part of 4DMT's efforts to advance durable treatments for retinal diseases. The company is also progressing with its Phase 3 trial for 4D-150 and developing 4D-710 for cystic fibrosis.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
